secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbbVie Inc. (ABBV)
CIK:        0001551152
Form:       8-K
Filed at:   2026-08-18T20:30:26+00:00
Accession:  0001104659-26-098367
Event type: debt
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbbVie completes $10B senior notes offering to fund Apogee acquisition
----------------------------------------------------------------------

- Issued $10.0B aggregate principal across 9 tranches: floating rate notes due 2028 and fixed-rate notes from 4.500% due 2028 to 6.100% due 2066.
- Net proceeds to fund cash consideration for Apogee Therapeutics acquisition and related fees; remainder for general corporate purposes.
- Special mandatory redemption at 101% of principal if Apogee deal terminates before closing (excludes 2056 and 2066 notes).
- Notes are unsecured, unsubordinated, rank equally with existing debt; make-whole redemption provisions apply to fixed-rate notes.
- Offering completed August 18, 2026; supplemental indenture No. 13 filed with trustee U.S. Bank Trust Company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1551152/000110465926098367/0001104659-26-098367-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1551152/000110465926098367/tm2623337d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-098367

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer